Skip to main content
Caplight Logo









ILIAS Biologics Inc.

ILIAS Biologics Inc.

Private
DaejeonHealthcare & Life Scienceshttps://iliasbio.com/

Last Round

Series B

Sep 28, 2020

Total Funding Raised

$50.89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ILIAS Biologics Inc. is a biotechnology company that develops exosome-based therapeutics for inflammatory and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

exosome therapeuticsengineered exosomesdrug delivery platformclinical-stage biotechintracellular deliverylarge molecule deliveryexosome cargo loadingextracellular vesiclesEV therapeuticsexosome manufacturingexosome targetingprotein deliveryundruggable targetsinflammatory disease therapeuticsCNS drug deliveryoncology drug deliveryexosome evaluation service

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ILIAS Biologics Inc. Comparables

Compare ILIAS Biologics Inc. with similar companies based on industry and business-model similarity.

ILIAS Biologics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SHIFTBIO
86%
Carus Bio
85%
ExoStemTech
84%

ILIAS Biologics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 28, 2020
Series AMay 1, 2018

ILIAS Biologics Inc. Investors

Notable investors and investment history

ILIAS Biologics Inc. investors
InvestorRounds
KIWOOM Securities Co., Ltd.Series B
Genie Asset ManagementSeries B
Meritz Securities Co., Ltd.Series B
Timefolio Asset ManagementSeries A, Series B
Daedeok Venture PartnersSeries A, Series B
HB InvestmentSeries A, Series B
Devsisters VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 9, representing 53% of headcount.

  • Nov 11, 2024

    Monthly visitors grew 95% MoM, reaching 3.7K.

ILIAS Biologics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ILIAS Biologics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ILIAS Biologics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersDaejeon
Employee Range17
Year Founded2015
Last FundingSep 28, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?